期刊文献+

Sex difference in the prevalence of metabolic syndrome and its relationship to BMI and age

下载PDF
导出
摘要 Objective:To investigate the prevalence of metabolic syndrome (MetS) in primary aldosteronism(PA) patients with different genders and relationship between body mass index(BMI), age and MetS. Methods:This study included 168 PA patients who were hospitalized in hypertension treatment center of Xinjiang Uygur Autonomous Region People' Hospital, including 94 male patients and 74 female patients and the backgrounds and biochemical parameters of two groups were compared. Based on this, the relationship between BMI, age and MetS were also analyzed. Results:The prevalence of MetS was significantly higher in male patients with PA than female patients with PA(83.0% vs 58.1%,P<0.001). Compared to PA patients without MetS, PA patients with MetS had a higher level of BMI and greater prevalence of obesity (P<0.05). According to the BMI stratification analysis, we found the prevalence of MetS was higher in obese groups than non-obese groups (P<0.05). Moreover, the obese male patients with PA had higher prevalence of every component of MetS and prevalence of MetS with 5 metabolic factors compared to the non-obese group (P<0.05);while the obese female patients with PA only had higher prevalence of abdominal obesity compared to the non-obese group (P<0.001). Among the patients classified by age, the both prevalence of MetS was higher in male than female, and there was no male:female ratio inverted in patients with PA after menopause. Conclusions:The prevalence of MetS in male patients with PA was higher than female patients with PA. In addition, the obese groups had the higher prevalence of MetS than non-obese groups.
出处 《Journal of Hainan Medical University》 2019年第24期16-22,共7页 海南医学院学报(英文版)
基金 National Health Committee Key Laboratory of Hypertension Clinical Research Non-profit Central Research Institute Fund of the Chinese Academy of Medical Sciences(No.2019PT330003).
  • 相关文献

参考文献2

二级参考文献14

  • 1Seifarth C, Trenkel S, Schobel H, et al. Influence of antihypertensive medication on aldosterone and renin concentration in the differential diagnosis of essential hypertension and primary aldosteronism. Eur J Endocrino1,2004,150:329-337.
  • 2Bochud M, Nussberger J, Bovet P, et al. Plasma aldosterone is indenpendently associated with the metabolic syndrome. Hypertension ,2006, 48:239-245.
  • 3Franeesco F, Giovanni F, Franco V, et al. The metabolic syndrome in primary aldosteronism. Curr Hypertens Rep ,2007,9 : 106-111.
  • 4Gilberta G, Vanessa R, Federica T, et al. Aldosterone as a key mediator of the eardiometabolie syndrome in primary aldosteronism:an observa- tional study. J Hypertens,2007,25 : 177-186.
  • 5Krug AW,Ehrbart-Bornstein M. Aldosterone and Metabolic syndrome is increased aldosterone in metabolic syndrome patients an additional risk factor? Hypertension ,2008,51 : 1252-1258.
  • 6Perkins JM,Davis SN. The renin-angiotensin-aldosterone system:a pivotal role in insulin sensitivity and glycemic control. Curr Opin Endocri- nol Diabetes Obes,2008,15 : 147-152.
  • 7Mossn LM, Carvajal CA, Maiz A, et al. A possible association between priming, aldosteronism and a lower beta-cell ruction. J Hypertens,2007, 25:2125-2130.
  • 8Giacchetti G, Sechi LA, Rilli S, et rune system, glucose metabolism Metab, 2005, 1 6 : 120 - 125.
  • 9al. The rennin-angiotensin-aldosteand diabetes. Trends Endocrinol Bochud M, Nussberger J, Borer P, et al. Plasma aldosterone is independently associated with the metabolic syndrome. Hypertension ,2006, 48 : 239-245.
  • 10Dahlof B, Devereux RB, Kjeldsen SE, et al. Cadiovascular morbidity and mortality in the Losartan lntmwention For Endpoint reduction in hyper- tension study (LIFE) :a randomized trail against atenolol. Lancet, 2002, 359:995-1003.

共引文献62

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部